The person depicted is a model used for illustrative purposes only.
Watch the MENVEO Clinical Study Design Video
SOLICITED ADVERSE REACTIONS IN ADOLESCENT PATIENTS 11 TO 18 YEARS OF AGE WITHIN 7 DAYS POSTVACCINATION1
SOLICITED ADVERSE REACTIONS IN INFANT AND TODDLER PATIENTS 2 TO 23 MONTHS OF AGE WHO RECEIVED MENVEO AT 2, 4, 6, AND 12 MONTHS OF AGE WITHIN 7 DAYS AFTER ANY DOSE1
*Rash was only graded as present or not present without a grading for severity.
†MENVEO plus routine vaccinations, including diphtheria toxoid, tetanus toxoid, and acellular pertussis (DTaP), inactivated poliovirus (IPV) types 1, 2, and 3, hepatitis B, Haemophilus influenzae type b (Hib), and 7-valent pneumococcal conjugate (PCV7) at doses 1, 2, 3; and PCV7, measles, mumps, rubella, varicella (MMRV), and hepatitis A vaccines at dose 4. Hepatitis B vaccine (HBV) and rotavirus vaccines were allowed according to Advisory Committee on Immunization Practices (ACIP) recommendations.
‡Routine vaccinations alone.
- Prescribing Information for MENVEO.
- Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9-S15.
- Meningococcal vaccines for preteens, teens. Centers for Disease Control and Prevention website. http://www.cdc.gov/features/meningococcal/. Updated April 18, 2016. Accessed October 6, 2017.
- Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed October 6, 2017.
- Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
- Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
- MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed October 6, 2017.
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
- Centers for Disease Control and Prevention website. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2005-2014. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed October 6, 2017.
- Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics. 2009;124(6):1633-1641.